Smoke without fire? Researchers question heated tobacco products

Industry Insight
Jul.22.2022

Heated tobacco products have soared in popularity as a "smoke free" alternative to cigarettes in recent years, but a peer-reviewed report has suggested their emissions could be considered smoke—a claim strongly rejected by the tobacco industry.

 

Smoke without fire? Researchers question heated tobacco products

Heated tobacco products, or HTPs, are often confused with e-cigarettes, which heat liquid that can contain nicotine but do not involve tobacco leaf.

HTPs instead use a high heat to decompose tobacco, via a process called pyrolysis, which does not set it on fire or burn it, therefore avoiding creating smoke.

 

The most popular and widely available HTP, Philip Morris International's IQOS, is an electronic device that heats a tobacco-filled, paper-wrapped, cigarette-like stick at a temperature of up to 350 degrees Celsius (662 degrees Fahrenheit).

 

Last month a review of the available research by experts in pyrolysis from Britain's Nottingham University found "chemical evidence that IQOS emissions fit the definition of both an aerosol and smoke."

 

The paper, published in the American Chemical Society's Omega journal, was funded by the STOP anti-tobacco initiative.

Its lead author Clement Uguna said that IQOS emissions contain chemical compounds that are "in normal tobacco smoke, bush burning and wood smoke".

 

"Hence smoke arises simply by heating organic substances and does not necessarily involve fire," he told AFP.

 

The paper also found that previous research on IQOS—the majority of which has been funded by the tobacco industry—had compared a stick to a typical cigarette.

 

However IQOS sticks are much smaller, containing around 200 milligrams of tobacco compared to 645 milligrams for a standard cigarette, it said.

 

Because research by Philip Morris International (PMI) did not use a "like against like" comparison, it "underestimated" the levels of harmful and potentially harmful constituents (HPHCs) from IQOS, the review added.

 

PMI said the level of HPHCs in IQOS emissions—per stick—was "reduced on average by 90-95 percent compared to cigarette smoke".

 

However that level fell to 68 percent when comparing the tobacco content of the two products, the Nottingham University experts said, calling for more research.

 

'Not smoke': PMI

 

PMI told AFP that the paper "misleadingly leverages pieces of the scientific assessment while omitting other important pieces of evidence".

 

"Numerous international combustion experts and a number of government agencies have reviewed the same evidence package and concluded that the IQOS aerosol produced is not smoke," it said.

 

Reto Auer, a doctor at Germany's University of Bern who has previously researched heated tobacco, praised the Omega paper, telling AFP it was "one of the rare reports to dare to tackle the question of 'smoke' so deeply".

 

Jamie Hartmann-Boyce of the Centre for Evidence-Based Medicine at Oxford University, an author of a highly regarded review on HTP science published earlier this year, said the "important" paper "made some very good points".

 

"I think mechanistically there are a lot of reasons to suspect HTPs might be more harmful than e-cigarettes and possibly less harmful than traditional cigarettes—but we really need more data," she told AFP.

 

'Difficult balance'

 

IQOS is available in more than 60 countries under widely varying regulations, and sticks come in flavours such as menthol, cherry and grape, which critics say help attract younger users.

 

Last month the European Commission proposed banning flavoured HTP varieties after stick sales in the EU soared more than 2,000 percent—from 934 million to nearly 20 billion—between 2018 and 2020.

 

PMI told AFP that the "proposal from the Commission is not underpinned by evidence".

 

"It fails to prove, for instance, that flavours pose any additional health risks or that they attract a significant proportion of non-nicotine users," it said.

 

Hartmann-Boyce said "there is every reason to be concerned about the extent to which the tobacco industry is manipulating the science and messages around new tobacco products."

 

But she warned it was a "difficult balance" to communicate the risks of such products because of the overwhelming damage done by cigarettes. Tobacco kills half its users, according to the World Health Organization.

 

"If we say something is safer than cigarettes, that is not saying it's safe—it's like saying that this knife is safer than a loaded gun," Hartmann-Boyce said.

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

JAMA Study: U.S. Vape Directories Fail to Sustainably Curb Unlisted Sales as Product Shifts May Redistribute Brand Share 2Firsts Recommended
JAMA Study: U.S. Vape Directories Fail to Sustainably Curb Unlisted Sales as Product Shifts May Redistribute Brand Share 2Firsts Recommended
A study by CDC Foundation researchers found no sustained decline in e-cigarette sales across Alabama, Oklahoma and Louisiana, the first three U.S. states to implement e-cigarette directory laws. Louisiana initially saw a significant sales decline, followed by a rebound and a persistent reduction in product availability. Sales also shifted from nontobacco-flavored disposables toward prefilled cartridges, with Vuse Alto driving much of the increase in menthol cartridges. By April 2025, unlisted products still accounted for more than half of e-cigarette nicotine sales in all three states.
Sep.18
Elf Bar Vape Explosion and Amputation Claim Spurs Coverage Suit, U.S. Insurer MUSIC Seeks Ruling It Owes No Duty to Defend or Indemnify Distributor i5
Elf Bar Vape Explosion and Amputation Claim Spurs Coverage Suit, U.S. Insurer MUSIC Seeks Ruling It Owes No Duty to Defend or Indemnify Distributor i5
Mesa Underwriters Specialty Insurance Company has asked a federal court in Washington to declare that it has no duty to defend or indemnify vape distributor i5 Distribution in a product liability case involving an Elf Bar BC5000. The plaintiff alleges that the disposable vape caught fire and exploded in his pocket, causing severe burns and ultimately requiring an above-the-knee amputation of his left leg. MUSIC is relying on a tobacco, nicotine or nicotine replacement products exclusion and a premises limitation endorsement. The court has not ruled on the coverage dispute.
News
Sep.10
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
The U.S. Food and Drug Administration authorized 11 ZYN ULTRA nicotine pouch products made by Swedish Match USA through the premarket tobacco product application pathway on August 21, 2026. Ten of the authorized products have a labeled nicotine content of 9 mg, while ZYN ULTRA Smooth was authorized at 11 mg. The reviews were conducted through FDA’s nicotine pouch PMTA pilot program. FDA has now authorized 43 nicotine pouch products, including 23 through the pilot.
Aug.24
Product | PMI Japan Launches SENTIA Passion Fruit Capsule, Expanding the IQOS ILUMA Flavor Portfolio
Product | PMI Japan Launches SENTIA Passion Fruit Capsule, Expanding the IQOS ILUMA Flavor Portfolio
Philip Morris Japan (PM Japan) has introduced SENTIA Passion Fruit Capsule, a new tobacco stick designed for the IQOS ILUMA heated tobacco platform. Featuring a crush-activated capsule, the product combines menthol with passion fruit flavor to provide an additional flavor experience. The product launched in Japan from August 3, 2026, through IQOS official channels, convenience stores and tobacco retailers.
Aug.04
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
InterTabac 2026: Further Sessions on Regulation, Market Access and Innovation Confirmed; 2FIRSTS to Host China Market Forum
InterTabac 2026: Further Sessions on Regulation, Market Access and Innovation Confirmed; 2FIRSTS to Host China Market Forum
InterTabac 2026 will bring together international experts to discuss European regulation, tax policy, Track & Trace, market access, retail impacts, consumer behavior and innovation. Sessions will also examine Poland’s tobacco-growing perspective and the growing fragmentation of Europe’s tobacco and nicotine market. Media partner 2FIRSTS will host the second “2FIRSTS Connect at InterTabac” on September 16, focusing on developments in China’s tobacco and nicotine industry.
Aug.06